



## Nanoparticles for theranostic, combining imaging and therapy

“See what to target, target what to see”

**NH TherAguix** is a clinical stage pharmaceutical company developing innovative nanomedicine that improve radiation therapy benefits without modifying current clinical workflows. Our leading product, [AGuIX®](#), is a nanoparticle designed to improve the localization of solid tumors and the outcomes of radiation therapy by a unique intravenous injection.

### *Technology*

Currently, ~2/3 of cancer patients receives radiation therapy during their treatment. One of the main radiation therapy challenges is to deliver a sufficient radiation dose in the tumor while sparing the surrounding healthy tissues.

[AGuIX®](#) **plays a key role in imaging.** Combined with MRI, [AGuIX®](#) allows an increase of tumor contrast after injection, helping the physician to localize and delineate with accuracy the tumor region. [AGuIX®](#) also allows to personalize the radiation therapy treatment for each patient by determining the optimal moment to perform the irradiation.

[AGuIX®](#) **plays a key role in radiation therapy.** Combined with the radiation therapy, [AGuIX®](#) amplifies the radiation efficacy locally in the tumor by acting as a radioenhancer and a radiosensitizer. This technology allows to treat radioresistant cancers and to minimize the radiation therapy secondary effects by decreasing the dose to healthy tissues.

[AGuIX® technology](#) is protected by 4 international patents and its efficacy has been demonstrated in [50+ scientific peer reviewed publications](#).

### **Clinical trials**

NH TherAguix achieved a key milestone in the leading product development with the completion of cGMP production of 1000 vials of [AGuIX®](#) and the successful validation of the toxicity and stability tests required by the French-FDA.

Recently, the green light for the first “in man injection” in the frame of a Phase 1 trial involving patients with brain metastasis was given by the ANSM (French FDA). This first trial will be performed by the radiotherapy service of the Grenoble University Hospital, France.

We are currently seeking financing to meet the funding requirements to complete the upcoming Phase 1 program and produce new batches of drugs for Phase 2.

### **The team**

NH TherAguix was founded on Dec 11th, 2015 by Prof. Olivier Tillement (CSO) and Géraldine Le Duc (CEO) after 10 years of scientific complicity, in the purpose of developing the AGuIX nanoparticles. The company is based in Eastern South of France (Lyon-Grenoble).

Beyond the co-founders, NH TherAguix's team is reinforced by a chemist (Francois Lux), a pharmacist (Sandrine Dufort) and and medical physicist (Alex Detappe). The team is particularly knowledgeable about drug formulations, pharmacology, *in vivo* and *in vitro* experimental imaging and radiotherapy .

[www.nhtheraguix.com](http://www.nhtheraguix.com)